{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:05:57Z","timestamp":1790399157571,"version":"4.1.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eiger Pharmaceuticals"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Reata Pharmaceuticals"},{"name":"United Healthcare"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ccm.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T07:09:47Z","timestamp":1562396987000},"page":"501-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Apostolos","family":"Perelas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Arrossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin B.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2019.05.001_bib1","first-page":"109","article-title":"Scleroderma-related interstitial lung disease","volume":"22","author":"Suliman","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib2","first-page":"2236","article-title":"Estimating the burden of scleroderma disease in Spain","volume":"34","author":"Villaverde-Hueso","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"10103","key":"10.1016\/j.ccm.2019.05.001_bib3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2019.05.001_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4615-4857-7_11","article-title":"Systemic sclerosis. A clinical overview","volume":"455","author":"Generini","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ccm.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2147\/DDDT.S99696","article-title":"Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis","volume":"10","author":"Sakkas","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.patbio.2015.03.003","article-title":"Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis","volume":"63","author":"Hua-Huy","year":"2015","journal-title":"Pathol Biol"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib10","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","article-title":"Treatment of systemic sclerosis\u2013related interstitial lung disease: a review of existing and emerging therapies","volume":"13","author":"Volkmann","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00109-014-1190-x","article-title":"Molecular and cellular basis of scleroderma","volume":"92","author":"Eckes","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J\u00a0Dermatol Sci"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ccm.2019.05.001_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/art.40862","article-title":"Prevalence, treatment and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib17","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung\u00a0disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0000000000000323","article-title":"Interstitial lung disease in systemic sclerosis","volume":"28","author":"Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/14397595.2015.1115455","article-title":"Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study","volume":"26","author":"Wangkaew","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"127","key":"10.1016\/j.ccm.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5606\/ArchRheumatol.2018.6630","article-title":"Clinical characteristics of systemic sclerosis with interstitial lung disease","volume":"33","author":"Jung","year":"2018","journal-title":"Arch Rheumatol"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.1780340405","article-title":"Predictors of survival in systemic sclerosis (scleroderma)","volume":"34","author":"Altman","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1753465817713680","article-title":"Evaluation and management approaches for scleroderma lung disease","volume":"11","author":"Schoenfeld","year":"2017","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2169\/internalmedicine.48.1714","article-title":"Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types","volume":"48","author":"Daimon","year":"2009","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1148\/radiol.2322031223","article-title":"CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia","volume":"232","author":"Desai","year":"2004","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.resinv.2016.05.004","article-title":"A\u00a0retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease","volume":"54","author":"Okamoto","year":"2016","journal-title":"Respir Investig"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib29","first-page":"121","article-title":"The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia","volume":"19","author":"Kim","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.rhu.0000152147.38706.db","article-title":"The lung in systemic sclerosis","volume":"11","author":"Steen","year":"2005","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib31","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23736\/S0026-4806.17.05285-5","article-title":"Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis","volume":"109","author":"Benfante","year":"2018","journal-title":"Minerva Med"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/BOR.0000000000000111","article-title":"Update on scleroderma-associated interstitial lung disease","volume":"26","author":"Fan","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib36","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/resp.13175","article-title":"Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease","volume":"23","author":"Takei","year":"2018","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib43","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.ccm.2019.05.001_bib44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib45","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.ccm.2019.05.001_bib46","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1056\/NEJMe068095","article-title":"Cyclophosphamide for scleroderma lung disease","volume":"354","author":"Martinez","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib47","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib48","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib49","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib51","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A\u00a0multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","article-title":"Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients","volume":"23","author":"Sari","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.ccm.2019.05.001_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10038","key":"10.1016\/j.ccm.2019.05.001_bib55","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2019.05.001_bib57","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-019-00928-3","article-title":"The effectiveness, safety, and tolerability of pirfenidone in idiopathic pulmonary fibrosis: a retrospective study","author":"Hanta","year":"2019","journal-title":"Adv Ther"},{"issue":"120","key":"10.1016\/j.ccm.2019.05.001_bib58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"1\u20133","key":"10.1016\/j.ccm.2019.05.001_bib59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(02)01758-2","article-title":"A\u00a0novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level","volume":"446","author":"Nakazato","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib60","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib61","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-015-0418-6","article-title":"Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000495046","article-title":"Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events","volume":"97","author":"Bendstrup","year":"2019","journal-title":"Respiration"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","article-title":"Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis","volume":"75","author":"Huang","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib64","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2019.05.001_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosisassociated interstitial lung disease","author":"Distler","year":"2019","journal-title":"New Eng J Med"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib66","first-page":"198","article-title":"Autologous stem cell transplantation in systemic sclerosis: a systematic review","volume":"35 Suppl 106","author":"Host","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib67","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","article-title":"Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American Society for Blood and Marrow Transplantation","volume":"24","author":"Sullivan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9790","key":"10.1016\/j.ccm.2019.05.001_bib68","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ccm.2019.05.001_bib69","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib72","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ejrad.2011.03.078","article-title":"Correlation between pretreatment or follow-up CT findings and therapeutic effect of autologous peripheral blood stem cell transplantation for interstitial pneumonia associated with systemic sclerosis","volume":"79","author":"Yabuuchi","year":"2011","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib73","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"43","key":"10.1016\/j.ccm.2019.05.001_bib74","doi-asserted-by":"crossref","first-page":"e1728","DOI":"10.1097\/MD.0000000000001728","article-title":"Registry of the Spanish network for systemic sclerosis","volume":"94","author":"Sime\u00f3n-Aznar","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib75","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10067-018-4390-x","article-title":"Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry","volume":"38","author":"Garc\u00eda-Hern\u00e1ndez","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"28","key":"10.1016\/j.ccm.2019.05.001_bib76","doi-asserted-by":"crossref","first-page":"e11437","DOI":"10.1097\/MD.0000000000011437","article-title":"Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease","volume":"97","author":"Niklas","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-017-1341-x","article-title":"Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension","volume":"19","author":"Morrisroe","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-018-0709-5","article-title":"An update on systemic sclerosis-associated pulmonary arterial hypertension: a review of the current literature","volume":"20","author":"Sundaram","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/2045893218757404","article-title":"Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort","volume":"8","author":"Lammi","year":"2018","journal-title":"Pulm Circ"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib80","first-page":"2347","article-title":"Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib81","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2009","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.001_bib82","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"G\u00fcnther","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib83","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/rheumatology\/kex351","article-title":"Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension","volume":"56","author":"Connolly","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib84","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.chest.2017.02.010","article-title":"Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes","volume":"152","author":"Ramjug","year":"2017","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib85","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/acr.22766","article-title":"Skin telangiectasia and the identification of a subset of systemic sclerosis patients with severe vascular disease","volume":"68","author":"Hurabielle","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib86","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib87","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma \u2013 a review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib88","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib89","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.1780350709","article-title":"Isolated diffusing capacity reduction in systemic sclerosis","volume":"35","author":"Steen","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib90","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib91","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib92","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib93","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib94","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival","volume":"63","author":"Humbert","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib95","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A\u00a0comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib97","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1378\/chest.13-3014","article-title":"Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry","volume":"146","author":"Chung","year":"2014","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.001_bib98","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3899\/jrheum.110512","article-title":"Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension","volume":"38","author":"Mathai","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib99","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1086\/682432","article-title":"Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease\u2013associated pulmonary hypertension","volume":"5","author":"Minai","year":"2015","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib101","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib102","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib103","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ccm.2019.05.001_bib104","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","article-title":"RISE-SSc: riociguat in diffuse cutaneous systemic sclerosis","volume":"122","author":"Distler","year":"2017","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib105","doi-asserted-by":"crossref","first-page":"e011028","DOI":"10.1136\/bmjopen-2016-011028","article-title":"Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol","volume":"6","author":"Calderone","year":"2016","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib106","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.healun.2016.09.001","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart\u2013lung transplant report\u20142016; focus theme: primary diagnostic indications for transplant","volume":"35","author":"Yusen","year":"2016","journal-title":"J\u00a0Hear Lung Transplant"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib107","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/BOR.0000000000000546","article-title":"Lung transplantation in scleroderma: recent advances and\u00a0lessons","volume":"30","author":"Jablonski","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cgh.2016.08.034","article-title":"Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life","volume":"15","author":"Crowell","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5500\/wjt.v7.i2.103","article-title":"Role of gastroesophageal reflux disease in lung transplantation","volume":"7","author":"Hathorn","year":"2017","journal-title":"World J Transplant"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-017-0650-z","article-title":"Lung transplantation in patients with systemic sclerosis","volume":"19","author":"Shah","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib111","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Prad\u00e8re","year":"2018","journal-title":"J\u00a0Hear Lung Transplant"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib112","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/37.12.1320","article-title":"A\u00a0study of the frequency of pericardial and pleural effusions in scleroderma","volume":"37","author":"Thompson","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"4 Suppl 91","key":"10.1016\/j.ccm.2019.05.001_bib113","first-page":"S136","article-title":"Pleural irregularity, a new ultrasound sign for the study of interstitial lung disease in systemic sclerosis and antisynthetase syndrome","volume":"33","author":"Pinal-Fernandez","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.rhu.0000135557.49432.56","article-title":"Spontaneous pneumothorax in scleroderma","volume":"10","author":"Yoon","year":"2004","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib115","first-page":"689","article-title":"Bilateral spontaneous pneumothorax in systemic sclerosis--report of two cases","volume":"17","author":"Ng","year":"1990","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib116","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s10067-016-3245-6","article-title":"Predictors of inpatient mortality in patients with systemic sclerosis: a case control study","volume":"35","author":"Sehra","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib117","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00296-017-3826-y","article-title":"Determinants of mortality in systemic sclerosis: a focused review","volume":"38","author":"Poudel","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib118","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000164720","article-title":"Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavage","volume":"78","author":"Damjanov","year":"2009","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib119","first-page":"132","article-title":"Ventilation distribution and small airway function in patients with systemic sclerosis","volume":"23","author":"Silva","year":"2017","journal-title":"Rev Port Pneumol (2006)"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib120","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/art.21225","article-title":"Risk of malignancy in scleroderma: a population-based cohort study","volume":"52","author":"Chatterjee","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.001_bib121","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib122","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2133.2010.09861.x","article-title":"Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study","volume":"163","author":"Olesen","year":"2010","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib123","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.001_bib124","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","article-title":"Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies","volume":"52","author":"Bonifazi","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib126","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/ard.2006.056424","article-title":"Risk factors for lung cancer in patients with scleroderma: a nested case-control study","volume":"66","author":"Pontifex","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib127","doi-asserted-by":"crossref","first-page":"e0117829","DOI":"10.1371\/journal.pone.0117829","article-title":"Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study","volume":"10","author":"Katzen","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1389-9457(02)00013-8","article-title":"Sleep disruption in systemic sclerosis (scleroderma) patients: clinical and polysomnographic findings","volume":"3","author":"Prado","year":"2002","journal-title":"Sleep Med"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib129","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s11325-013-0834-3","article-title":"Obstructive sleep apnea is common in patients with interstitial lung disease","volume":"17","author":"Pihtili","year":"2013","journal-title":"Sleep Breath"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","article-title":"Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)","volume":"52","author":"Sharp","year":"1972","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.berh.2016.03.002","article-title":"Mixed connective tissue disease","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib132","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00005792-198403000-00003","article-title":"A\u00a0prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease","volume":"63","author":"Sullivan","year":"1984","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.001_bib133","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00004728-200205000-00006","article-title":"Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT","volume":"26","author":"Saito","year":"2002","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.001_bib134","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1136\/annrheumdis-2011-201253","article-title":"Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study","volume":"71","author":"Gunnarsson","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.001_bib135","first-page":"648","article-title":"Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement","volume":"36","author":"Narula","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib136","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/keh575","article-title":"Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD)","volume":"44","author":"Bodolay","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.ccm.2019.05.001_bib137","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejrad.2018.08.005","article-title":"Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis\/dermatomyositis","volume":"107","author":"Yamanaka","year":"2018","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib138","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.001_bib139","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.rmed.2008.12.018","article-title":"Esophageal involvement and interstitial lung disease in mixed connective tissue disease","volume":"103","author":"Fagundes","year":"2009","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.ccm.2019.05.001_bib141","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib142","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34 Suppl 100","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib143","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2016.12.013","article-title":"Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease","volume":"36","author":"Courtwright","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.001_bib144","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L","article-title":"Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings","volume":"42","author":"Burdt","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.001_bib145","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3899\/jrheum.121272","article-title":"Clinical course, prognosis, and causes of death in mixed connective tissue disease","volume":"40","author":"Hajas","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.001_bib146","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1253\/circj.CJ-17-0351","article-title":"Predictors of favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease","volume":"82","author":"Yasuoka","year":"2018","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.001_bib147","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:57:59Z","timestamp":1759453079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523119300292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":147,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0272523119300292"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2019.05.001","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}